Skip NavigationSkip to Content
Return Return to Search Results

CD164 identifies CD4+ T cells highly expressing genes associated with malignancy in Sezary syndrome: the Sezary signature genes, FCRL3, Tox, and miR-214

  1. Author:
    Benoit, B. M.
    Jariwala, N.
    O'Connor, Geraldine
    Oetjen, L. K.
    Whelan, T. M.
    Werth, A.
    Troxel, A. B.
    Sicard, H.
    Zhu, L.
    Miller, C.
    Takeshita, J.
    McVicar, Daniel
    Kim, B. S.
    Rook, A. H.
    Wysocka, M.

  2. Author Address

    Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, 421 Curie Blvd, 1049 BRB, Philadelphia, PA, 19104, USA. National Cancer Institute, Cancer and Inflammation Program, Frederick, MD, USA. Division of Dermatology, Department of Medicine, Washington University, St. Louis, MO, USA. The Division of Biology and Biomedical Sciences, Washington University, St. Louis, MO, USA. Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Innate Pharma, Research and Drug Development, Marseille, France. Department of Anesthesiology, Washington University, St. Louis, MO, USA. Department of Pathology and Immunology, Washington University, St. Louis, MO, USA. Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, 421 Curie Blvd, 1049 BRB, Philadelphia, PA, 19104, USA. mwysocka@mail.med.upenn.edu.
    1. Year: 2017
    2. Date: Jan
    3. Epub Date: 10/20/2016
  2. Journal: Archives of dermatological research
    1. 309
    2. 1
    3. Pages: 11-19
  4. Type of Article: Article
  5. ISSN: 0340-3696
  1. Abstract:

    Sezary syndrome (SS), a leukemic variant of cutaneous T-cell lymphoma (CTCL), is associated with a significantly shorter life expectancy compared to skin-restricted mycosis fungoides. Early diagnosis of SS is, therefore, key to achieving enhanced therapeutic responses. However, the lack of a biomarker(s) highly specific for malignant CD4+ T cells in SS patients has been a serious obstacle in making an early diagnosis. We recently demonstrated the high expression of CD164 on CD4+ T cells from Sezary syndrome patients with a wide range of circulating tumor burdens. To further characterize CD164 as a potential biomarker for malignant CD4+ T cells, CD164+ and CD164-CD4+ T cells isolated from patients with high-circulating tumor burden, B2 stage, and medium/low tumor burden, B1-B0 stage, were assessed for the expression of genes reported to differentiate SS from normal controls, and associated with malignancy and poor prognosis. The expression of Sezary signature genes: T plastin, GATA-3, along with FCRL3, Tox, and miR-214, was significantly higher, whereas STAT-4 was lower, in CD164+ compared with CD164-CD4+ T cells. While Tox was highly expressed in both B2 and B1-B0 patients, the expression of Sezary signature genes, FCRL3, and miR-214 was associated predominantly with advanced B2 disease. High expression of CD164 mRNA and protein was also detected in skin from CTCL patients. CD164 was co-expressed with KIR3DL2 on circulating CD4+ T cells from high tumor burden SS patients, further providing strong support for CD164 as a disease relevant surface biomarker.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1007/s00403-016-1698-8
  3. PMID: 27766406
  4. View record in Web of Science®
  5. WOS: 000392060800002

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel